🇺🇸 FDA
Patent

US 9539231

Method for treating triple-negative breast cancer using AMPI-109

granted A61KA61K31/215A61K31/337

Quick answer

US patent 9539231 (Method for treating triple-negative breast cancer using AMPI-109) held by The Regents of the University of Colorado, a Body Corporate expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/215, A61K31/337, A61K31/704